{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:48:10Z","timestamp":1787500090618,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002979","name":"Dalian Institute of Chemical Physics","doi-asserted-by":"publisher","award":["DICP TMSR201601"],"award-info":[{"award-number":["DICP TMSR201601"]}],"id":[{"id":"10.13039\/501100002979","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.U1508221"],"award-info":[{"award-number":["No.U1508221"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81803706"],"award-info":[{"award-number":["81803706"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["ZZBS201803"],"award-info":[{"award-number":["ZZBS201803"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.vascn.2020.106682","type":"journal-article","created":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T20:00:53Z","timestamp":1582142453000},"page":"106682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Systematic characterization of AT1 receptor antagonists with label-free dynamic mass redistribution assays"],"prefix":"10.1016","volume":"102","author":[{"given":"Lala","family":"Qu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jixia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmiao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vascn.2020.106682_bb0005","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0026-895X(25)09072-8","article-title":"Modulation of angiotensin-II binding affinity by allosteric interaction of polyvinyl sulfate with an intracellular domain of the DUP-753 sensitive angiotensin-II receptor of bovine adrenal glomerulosa","volume":"41","author":"Boulay","year":"1992","journal-title":"Molecular Pharmacology"},{"issue":"6","key":"10.1016\/j.vascn.2020.106682_bb0010","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1161\/01.CIR.103.6.904","article-title":"Angiotensin II type 1 receptor blockers","volume":"103","author":"Burnier","year":"2001","journal-title":"Circulation"},{"issue":"9204","key":"10.1016\/j.vascn.2020.106682_bb0015","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(99)10365-9","article-title":"Angiotensin II receptor antagonists","volume":"355","author":"Burnier","year":"2000","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vascn.2020.106682_bb0020","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/j.1476-5381.1993.tb13877.x","article-title":"Pharmacological profile of valsartan - a potent, orally-active, nonpeptide antagonist of the angiotensin-II AT1 receptor subtype","volume":"110","author":"Criscione","year":"1993","journal-title":"British Journal of Pharmacology"},{"issue":"12","key":"10.1016\/j.vascn.2020.106682_bb0025","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/j.febslet.2011.05.026","article-title":"Tyrphostin analogs are GPR35 agonists","volume":"585","author":"Deng","year":"2011","journal-title":"FEBS Letters"},{"issue":"3","key":"10.1016\/j.vascn.2020.106682_bb0030","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.vascn.2013.07.005","article-title":"Label-free cell phenotypic assessment of the biased agonism and efficacy of agonists at the endogenous muscarinic M-3 receptors","volume":"68","author":"Deng","year":"2013","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"26","key":"10.1016\/j.vascn.2020.106682_bb0035","doi-asserted-by":"crossref","first-page":"10370","DOI":"10.1039\/c3ra40426a","article-title":"Label-free cell phenotypic assessment of the molecular mechanism of action of epidermal growth factor receptor inhibitors","volume":"3","author":"Deng","year":"2013","journal-title":"RSC Advances"},{"issue":"19","key":"10.1016\/j.vascn.2020.106682_bb0040","doi-asserted-by":"crossref","first-page":"8232","DOI":"10.1021\/ac301495n","article-title":"Probing biochemical mechanisms of action of muscarinic M3 receptor antagonists with label-free whole cell assays","volume":"84","author":"Deng","year":"2012","journal-title":"Analytical Chemistry"},{"issue":"3\u20134","key":"10.1016\/j.vascn.2020.106682_bb0045","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/10799890903079844","article-title":"A 100K well screen for a muscarinic receptor using the epic (R) label-free system - a reflection on the benefits of the label-free approach to screening seven-transmembrane receptors","volume":"29","author":"Dodgson","year":"2009","journal-title":"Journal of Receptors and Signal Transduction"},{"issue":"5","key":"10.1016\/j.vascn.2020.106682_bb0050","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1089\/adt.2006.4.583","article-title":"Label-free cell-based assays with optical biosensors in drug discovery","volume":"4","author":"Fang","year":"2006","journal-title":"Assay and Drug Development Technologies"},{"issue":"10","key":"10.1016\/j.vascn.2020.106682_bb0055","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.3390\/s7102316","article-title":"Non-invasive optical biosensor for probing cell signaling","volume":"7","author":"Fang","year":"2007","journal-title":"Sensors"},{"key":"10.1016\/j.vascn.2020.106682_bb0060","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2121-8-24","article-title":"Optical biosensor differentiates signaling of endogenous PAR(1) and PAR(2) in A431 cells","volume":"8","author":"Fang","year":"2007","journal-title":"BMC Cell Biology"},{"issue":"5","key":"10.1016\/j.vascn.2020.106682_bb0065","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1529\/biophysj.105.077818","article-title":"Resonant waveguide grating biosensor for living cell sensing","volume":"91","author":"Fang","year":"2006","journal-title":"Biophysical Journal"},{"key":"10.1016\/j.vascn.2020.106682_bb0070","series-title":"2005 27th Annual International Conference of the IEEE Engineering in Medicine and Biology Society","first-page":"666","article-title":"Optical biosensors for monitoring dynamic mass redistribution in living cells mediated by epidermal growth factor receptor activation","volume":"1-7","author":"Fang","year":"2005"},{"key":"10.1016\/j.vascn.2020.106682_bb0080","doi-asserted-by":"crossref","unstructured":"Ferrie, A. M., Sun, H., Zaytseva, N., & Fang, Y. (2014). Divergent label-free cell phenotypic pharmacology of ligands at the overexpressed beta 2-adrenergic receptors. Scientific Reports, 4. doi: 10.1038\/srep03828.","DOI":"10.1038\/srep03828"},{"key":"10.1016\/j.vascn.2020.106682_bb0075","first-page":"248","article-title":"Non-invasive profiling of endogenous G-protein-coupled-receptors in living cells with optical biosensors","volume":"27","author":"Fang","year":"2006","journal-title":"Acta Pharmacologica Sinica"},{"issue":"2","key":"10.1016\/j.vascn.2020.106682_bb0085","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0014-2999(99)00205-8","article-title":"Insurmountable angiotensin AT(1) receptor antagonists: The role of tight antagonist binding","volume":"372","author":"Fierens","year":"1999","journal-title":"European Journal of Pharmacology"},{"issue":"5","key":"10.1016\/j.vascn.2020.106682_bb0090","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s002100100396","article-title":"Differential effects of eprosartan and losartan at prejunctional angiotensin II receptors","volume":"363","author":"Guimaraes","year":"2001","journal-title":"Naunyn-Schmiedebergs Archives of Pharmacology"},{"issue":"9","key":"10.1016\/j.vascn.2020.106682_bb0095","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1021\/acsmedchemlett.6b00273","article-title":"The added value of assessing ligand-receptor binding kinetics in drug discovery","volume":"7","author":"Guo","year":"2016","journal-title":"ACS Medicinal Chemistry Letters"},{"issue":"2","key":"10.1016\/j.vascn.2020.106682_bb0100","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0922-4106(95)90103-5","article-title":"Kinetic studies on the interaction of nonlabeled antagonists with the angiotensin-II receptor","volume":"289","author":"Hara","year":"1995","journal-title":"European Journal of Pharmacology-Molecular Pharmacology Section"},{"key":"10.1016\/j.vascn.2020.106682_bb0105","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.phrs.2016.04.018","article-title":"Label-free cell phenotypic profiling and pathway deconvolution of neurotensin receptor-1","volume":"108","author":"Hou","year":"2016","journal-title":"Pharmacological Research"},{"issue":"7","key":"10.1016\/j.vascn.2020.106682_bb0110","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/sj.bjp.0707323","article-title":"Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT(1) receptor","volume":"151","author":"Le","year":"2007","journal-title":"British Journal of Pharmacology"},{"issue":"1","key":"10.1016\/j.vascn.2020.106682_bb0115","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/adt.2007.126","article-title":"Evaluation of dynamic mass redistribution technology for pharmacological studies of recombinant and endogenously expressed G protein-coupled receptors","volume":"6","author":"Lee","year":"2008","journal-title":"Assay and Drug Development Technologies"},{"issue":"8","key":"10.1016\/j.vascn.2020.106682_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0203021","article-title":"NOP receptor pharmacological profile - a dynamic mass redistribution study","volume":"13","author":"Malfacini","year":"2018","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.vascn.2020.106682_bb0125","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0163-7258(97)82002-5","article-title":"Losartan, an orally active angiotensin (AT(1)) receptor antagonist: A review of its efficacy and safety in essential hypertension","volume":"74","author":"McIntyre","year":"1997","journal-title":"Pharmacology & Therapeutics"},{"issue":"2","key":"10.1016\/j.vascn.2020.106682_bb0130","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/hr.2012.147","article-title":"Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartan","volume":"36","author":"Miura","year":"2013","journal-title":"Hypertension Research"},{"key":"10.1016\/j.vascn.2020.106682_bb0135","doi-asserted-by":"crossref","DOI":"10.1186\/2050-6511-14-17","article-title":"Label-free integrative pharmacology on-target of opioid ligands at the opioid receptor family","volume":"14","author":"Morse","year":"2013","journal-title":"Bmc Pharmacology & Toxicology"},{"issue":"3","key":"10.1016\/j.vascn.2020.106682_bb0140","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/jpet.110.176636","article-title":"In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, Azilsartan, in receptor binding and function studies","volume":"336","author":"Ojima","year":"2011","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"12","key":"10.1016\/j.vascn.2020.106682_bb0145","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1021\/jm0204237","article-title":"Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites","volume":"46","author":"Schmidt","year":"2003","journal-title":"Journal of Medicinal Chemistry"},{"issue":"7","key":"10.1016\/j.vascn.2020.106682_bb0150","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1161\/01.CIR.98.7.711","article-title":"A(2A)-adenosine receptor reserve for coronary vasodilation","volume":"98","author":"Shryock","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.vascn.2020.106682_bb0155","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jhazmat.2017.03.025","article-title":"Label-free pharmacological profiling based on dynamic mass redistribution for characterization and authentication of hazardous natural products","volume":"333","author":"Song","year":"2017","journal-title":"Journal of Hazardous Materials"},{"issue":"4","key":"10.1016\/j.vascn.2020.106682_bb0160","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/sj.bjp.0702398","article-title":"Distinction between surmountable and insurmountable selective AT(1) receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT(1) receptors","volume":"126","author":"Vanderheyden","year":"1999","journal-title":"British Journal of Pharmacology"},{"issue":"8","key":"10.1016\/j.vascn.2020.106682_bb0165","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0006-2952(99)00403-7","article-title":"Reversible and syntopic interaction between angiotensin receptor antagonists on Chinese hamster ovary cells expressing human angiotensin II type I receptors","volume":"59","author":"Vanderheyden","year":"2000","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.vascn.2020.106682_bb0170","first-page":"S15","article-title":"The effects of candesartan on human AT(1) receptor-expressing Chinese hamster ovary cells","volume":"10","author":"Vauquelin","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1016\/j.vascn.2020.106682_bb0175","first-page":"69","article-title":"AT1 receptor antagonists. Current medicinal chemistry","volume":"2","author":"Verheijen","year":"2004","journal-title":"Cardiovascular and hematological agents"},{"issue":"1","key":"10.1016\/j.vascn.2020.106682_bb0180","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1476-5381.1993.tb13800.x","article-title":"Pharmacological characterization of the novel nonpeptide angiotensin-II receptor antagonist, BIBR-277","volume":"110","author":"Wienen","year":"1993","journal-title":"British Journal of Pharmacology"},{"issue":"2","key":"10.1016\/j.vascn.2020.106682_bb0185","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/1056-8719(93)90055-J","article-title":"The competitive and noncompetitive antagonism of ReceptorMediated drug actions in the presence of spare receptors","volume":"29","author":"Zhu","year":"1993","journal-title":"Journal of Pharmacological and Toxicological Methods"}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871920300113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871920300113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:16:18Z","timestamp":1778796978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056871920300113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":37,"alternative-id":["S1056871920300113"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2020.106682","relation":{},"ISSN":["1056-8719"],"issn-type":[{"value":"1056-8719","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic characterization of AT1 receptor antagonists with label-free dynamic mass redistribution assays","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2020.106682","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106682"}}